| abstract |
Use of an antagonist selected from the group consisting of: (a) antagonists of neurokinin-1 (NK 1 ), neurokinin-2 (NK 2 ) and neurokinin-3 (NK 3 ) receptors, (b) antagonists of NK 1 and NK 2 receptors, (c) antagonists of NK 2 and NK 3 receptors, (d) antagonists of NK 1 and NK 3 receptors, (e) antagonists of NK 1 receptors, and (f) antagonists of NK 2 to treat symptoms and disorders associated with a production and/or secretion of androgen. One aspect of the invention relates to the use of antagonists to suppress production/secretion of androgens in mammals suffering from an androgen-dependent disease, such as benign prostatic hyperplasia and prostatic carcinoma. |